Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Abstract Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC). Methods Patients with UC were enrolled independent of tumor homologous recombination deficiency (HRD)...

Full description

Bibliographic Details
Main Authors: P. Grivas, Y. Loriot, R. Morales-Barrera, M. Y. Teo, Y. Zakharia, S. Feyerabend, N. J. Vogelzang, E. Grande, N. Adra, A. Alva, A. Necchi, A. Rodriguez-Vida, S. Gupta, D. H. Josephs, S. Srinivas, K. Wride, D. Thomas, A. Simmons, A. Loehr, R. L. Dusek, D. Nepert, S. Chowdhury
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Bladder cancer
Urothelial carcinoma
PARP inhibitor
Rucaparib
Genomic biomarkers
Online Access:https://doi.org/10.1186/s12885-021-08085-z

Internet

https://doi.org/10.1186/s12885-021-08085-z

Similar Items